Moreover, upon activation of its receptor, GRP109A, butyrate can inhibit several key pro-inflammatory pathways that are highly involved in CRC, such as protein kinase B or Akt (PKB/Akt) and NF-κB signaling pathways (Chen et al., 2018). This evidence concerns the gene AKT1 and colorectal carcinoma.